5 Key Takeaways

• 1

  Vaccine rollout faces logistical challenges in delivery, transport, and storage, impacting equitable access globally.

• 2

  Between 2 billion and 5 billion people in low- and middle-income countries await COVID-19 vaccines.

• 3

  Local manufacturing hubs can reduce distribution obstacles and improve vaccine access by utilizing local knowledge.

• 4

  The pandemic highlighted the need for increased R&D for emerging infectious diseases beyond COVID-19.

• 5

  Only 7% of the pharmaceutical pipeline targets children under 12, raising concerns about access for young populations.